Equillium Full Year 2024 Earnings: Beats Expectations

Equillium (NASDAQ:EQ) Full Year 2024 Results

Key Financial Results

• Revenue: US$41.1m (up 14% from FY 2023).
• Net loss: US$8.07m (loss narrowed by 40% from FY 2023).
• US$0.23 loss per share (improved from US$0.38 loss in FY 2023).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Equillium Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) also surpassed analyst estimates by 39%.

Looking ahead, revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 39% from a week ago.

Risk Analysis

We should say that we've discovered 4 warning signs for Equillium (2 are concerning!) that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.